URGN · UroGen Pharma
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $31.64
Note written ·
Price against the kill line
17.3% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $31.64, on record since 11 November 2026. The shares are down 46.7% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $31.64, just under the 200-day average of closes, which would show the shares leading the S&P 500 again; fourth-quarter 2026 ZUSDURI revenue growth faster than the third quarter's 35% would also show it.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 4 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 89.0
- Revenue, change on a year (%)
- +223.9
- Gross margin (%)
- 91.6
- Operating margin (%)
- 9.4
- Free cash flow, four quarters ($M)
- −132
- Net cash, cash less debt ($M)
- −110
- Enterprise value to sales (×)
- 5.6
- Free-cash-flow yield (%)
- −10.3
All filed numbers
What UroGen Pharma reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 89.0 | +223.9 | 91.6 | 9.4 |
| first filed | 72.5 | +199.2 | 90.9 | 0.2 |
| first filed | 51.0 | +151.6 | 91.9 | −39.8 |
| first filed | 37.8 | +54.0 | 91.3 | −50.5 |
| first filed | 27.5 | +9.0 | 88.1 | −99.7 |
| first filed | 24.2 | +10.8 | 85.3 | −171.2 |
| Pre-tax income ($M) | −0.4 |
| Net income ($M) four quarters: −65.8 | −1.5 |
| Diluted shares, change on a year (%) | Not reported |
| Operating cash flow ($M) | −132 |
| Capital spending ($M) | 0.2 |
| Free cash flow ($M) | −132 |
| Cash and short-term investments ($M) | 90.5 |
| Debt ($M) long-term debt | 200 |
| Net cash, cash less debt ($M) | −110 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 117 |
| Inventory ($M) | 25.1 |
| Shareholders' equity ($M) | −125 |
| Market value ($M) | 1,284 |
| Enterprise value, market value plus net debt ($M) | 1,394 |
| Enterprise value to sales (×) | 5.6 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | Not meaningful |
| Free-cash-flow yield (%) | −10.3 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 11.4% of shares outstanding sold short, 4.9 days of average trading to cover, −27.8% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $3.0M |
| 12 monthsfrom | $0 | $4.8M |
The thesis
UroGen Pharma's ZUSDURI bladder-cancer launch is still growing, but growth is slowing, and the shares are more likely to lag the S&P 500 over the next three months. Third-quarter 2026 ZUSDURI net revenue was $68.0 million, up 35% from the second quarter, per the company's 4 November 2026 release. The fourth-quarter ZUSDURI figure, expected in early 2027, settles whether the slowdown is a pause or a trend.
The shares closed at $26.39 on 12 November 2026, 45.3% below their level three months earlier and 48.1% below the 52-week intraday high of $50.81 set on 19 August 2026. The price already reflects a launch that decelerated from 73% sequential growth in the second quarter to 35% in the third. It has not yet been tested against fourth-quarter revenue.
Bullish and bearish views on UroGen Pharma Ltd.
The bull case on UroGen Pharma Ltd. (URGN), in brief: launch revenue keeps rising. The bear case: growth slowed sharply.
Bull case
- Launch revenue keeps rising. ZUSDURI net revenue reached $68.0 million in the third quarter of 2026 from $50.4 million in the second, per UroGen's 4 November 2026 release. Total revenue was $89.0 million versus $27.5 million a year earlier.
- Repeat prescribing is expanding. At 30 September 2026 UroGen counted 662 unique ZUSDURI prescribers and 331 repeat prescribers, up from 452 and 204 at 30 June 2026. Activated sites rose to 1,538 from 1,444.
- The loss has nearly closed. The third-quarter net loss was $1.5 million, or $0.03 per share, versus $33.3 million, or $0.69 per share, a year earlier (UroGen release, 4 November 2026).
- The pipeline is advancing. The U.S. Food and Drug Administration (FDA) accepted the UGN-103 new drug application with a target action date of 14 June 2027, UroGen announced on 19 October 2026. The first patient was dosed in the UGN-501 Phase 1 trial on 2 November 2026.
- Analysts remain positive. Guggenheim kept its Buy rating on 5 November 2026 and lowered its price target to $56 from $58, as Benzinga reported.
Bear case
- Growth slowed sharply. Sequential ZUSDURI growth fell from 73% in the second quarter to 35% in the third, per UroGen's releases of 5 August 2026 and 4 November 2026. UroGen gave no full-year ZUSDURI revenue guidance.
- JELMYTO guidance was cut. UroGen lowered 2026 JELMYTO revenue guidance to about $90 million from $97–101 million on 4 November 2026. Third-quarter JELMYTO revenue was $21.0 million versus $25.7 million a year earlier.
- Cash is falling. Cash, cash equivalents and marketable securities were $90.5 million at 30 September 2026, down from $108.0 million at 30 June 2026. Guidance for 2026 operating expenses is $260–270 million.
- Dilution remains possible. UroGen took $75.0 million of additional borrowings from Pharmakon Advisors in the first quarter of 2026. A prepaid forward obligation to RTW Investments produced $4.5 million of non-cash financing expense in the third quarter.
- Executives have sold shares. SEC Form 4 filings show Chief Medical Officer Mark Schoenberg sold 60,677 shares at $47.05 on 20 August 2026. Chief Financial Officer Chris Degnan sold 2,202 shares at $36.69 on 8 October 2026.
Price setup
The shares closed at $26.39 on 12 November 2026. That is above the $24.75 close of 6 November 2026 and the $25.32 close of 10 November 2026, and well above the 52-week closing low of $17.00 on 30 March 2026.
Both moving averages sit above the price. The 50-day average of closes is $37.38 and the 200-day average is $31.66, as of the 12 November 2026 close. The distance to the 200-day average, about $5 per share, is the nearest test of whether buyers return before fourth-quarter revenue is reported.
The 52-week intraday high of $50.81 on 19 August 2026 marks where the shares stood before the second-quarter launch surge was followed by a slower third quarter.
Catalysts ahead
- ~1 March 2027 (est.): Fourth-quarter and full-year 2026 results; date unconfirmed. ZUSDURI revenue growth above the third quarter's 35% would show the launch re-accelerating; revenue near or below $68.0 million would show the slowdown continuing.
- 14 June 2027: FDA target action date for the UGN-103 new drug application. It is the next regulatory decision on extending the franchise to recurrent low-grade intermediate-risk bladder cancer.
What would change the view
A daily close above $31.64, just under the 200-day average of closes, which would show the shares leading the S&P 500 again; fourth-quarter 2026 ZUSDURI revenue growth faster than the third quarter's 35% would also show it.
What it trades with
UroGen trades on its own launch numbers and FDA calendar. Its moves track small- and mid-cap biotech sentiment and the funding climate for loss-making commercial drugmakers more than any single sector group.
Guggenheim's $56 target sits far above the $26.39 close, so further analyst revisions after the third-quarter report are the clearest read on sentiment. The 14 June 2027 FDA date on UGN-103 falls after the three-month window.
The evidence, claim by claim (8)
- Third-quarter 2026 ZUSDURI net product revenue was $68.0 million, up 35% from the second quarter; total revenue was $89.0 million versus $27.5 million a year earlier. UroGen third-quarter 2026 results release (8-K exhibit) · as of
- JELMYTO third-quarter net product revenue was $21.0 million versus $25.7 million a year earlier; 2026 JELMYTO guidance was lowered to about $90 million from $97–101 million. UroGen third-quarter 2026 results release (8-K exhibit) · as of
- At 30 September 2026 UroGen counted 1,538 activated sites, 662 unique ZUSDURI prescribers and 331 repeat prescribers, versus 1,444, 452 and 204 at 30 June 2026. UroGen third-quarter 2026 results release (8-K exhibit) · as of
- Cash, cash equivalents and marketable securities were $90.5 million at quarter-end, versus $108.0 million at 30 June 2026; net loss was $1.5 million, versus $33.3 million a year earlier. UroGen third-quarter 2026 results release (8-K exhibit) · as of
- Guggenheim kept a Buy rating and lowered its price target to $56 from $58. Benzinga · as of
- The FDA accepted the UGN-103 new drug application with a target action date of 14 June 2027. UroGen announcement via UroToday and OncLive · as of
- Chief Medical Officer Mark Schoenberg sold 60,677 shares at $47.05 on 20 August 2026; Chief Financial Officer Chris Degnan sold 2,202 shares at $36.69 on 8 October 2026. SEC Form 4 filings · as of
- The shares closed at $26.39, 48.1% below the 52-week intraday high of $50.81 set on 19 August 2026; the 3-month price change was −45.3%. Adjusted daily closes · as of
Sources
- UroGen Pharma Ltd. - Form 8-K - FY2026 · sec.gov ·